Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...
Brighton and Sussex Medical School and Royal Sussex County Hospital researchers have published an analysis of Francis ...
A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback